Genmab released new Phase II data for HuMax-CD20 demonstrating its effectiveness as an experimental antibody therapy for rheumatoid arthritis. Although the drug--also called Ofatumumab--did not do better than MabThera, a competing drug from Roche, researchers said the data warranted a push into late-stage trials in the last half of this year. GlaxoSmithKline bought the global rights to HuMax-CD20 in a deal worth a potential $2.1 billion payoff. Initial research has focused on its utility as a treatment for blood cancers, but a big potential payoff would come with an approval for use against RA.
- see this release on the data
- check out the AFX report for more